AIF1 and neoplasm: This trend is in line with previous Iba-1 immunohistochemistry data [31], which reported a 2.4-fold increase in the percentage of Iba-1 stained area for TMZ-treated tumours (when narrowing groups to control vs. high response cases, see [24,31] for further details).